Human recombinant erythropoietin

DRUG4 trials

Sponsors

University of Calgary, Seoul National University Bundang Hospital, Tanta University, Universitaire Ziekenhuizen KU Leuven

Conditions

Acute Myocardial InfarctionBrain InjuryCardiac SurgeryHypoxic Ischemic EncephalopathyReperfusion Injury

Phase 1

Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)

CompletedNCT00945789

Tanta UniversityHypoxic Ischemic Encephalopathy

Start: 2007-10-31End: 2009-06-30Updated: 2009-09-28

Phase 2

The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)

CompletedNCT00336466

University of CalgaryBrain Injury, Cardiac Surgery

Start: 2004-09-30End: 2005-05-31Target: 32Updated: 2007-11-27

Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)

CompletedNCT02251041

Universitaire Ziekenhuizen KU LeuvenReperfusion Injury

Start: 2014-09-30End: 2019-08-31Updated: 2024-08-23

Phase 4

The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction

CompletedNCT00882466

Seoul National University Bundang HospitalAcute Myocardial Infarction

Start: 2008-05-31End: 2009-02-28Updated: 2009-04-17

Related Papers

Effect of a Combined Drug Approach on the Severity of Ischemia-Reperfusion Injury During Liver Transplant

JAMA Network Open2023-02-2811 citations

The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention.

2010-03-0237 citations